This podcast will explore the various influences that the gut microbiome may have on the metabolism of drugs. This in turn may influence the way drugs are designed and formulated to achieve the best therapeutic outcome for patients.
Drug metabolism is a central area of research for effective drug design and therapy. What has been well explored is the metabolism of drugs after they enter the body following oral absorption. The main organ for systemic metabolism of drugs is the liver which metabolizes drugs into more hydrophilic metabolites to be excreted mainly with the urine. Other drugs and their metabolites may be excreted with the feces or via other pathways.
However, what has just recently gained interest is the presystemic metabolism of drugs by bacteria in the intestinal tract. Since nearly 85% of all drugs on the market are given via the oral route, consideration of what happens to the drug after it is released from its dosage form is an important part of providing patients with the best possible therapy depending on their condition and health status.
This podcast will explore the various influences that the gut microbiome may have on the metabolism of drugs. This in turn may influence the way drugs are designed and formulated to achieve the best therapeutic outcome for patients.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.